Main menu

Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping


Over 90% of people carry variants that could impact drug efficacy or safety. Here, Peng and Lin et al. validated Oxford Nanopore sequencing for accurate, haplotype-resolved testing of 35 pharmacogenomic targets, achieving high accuracy and enabling genome-wide genotyping — a scalable, cost-effective step towards truly personalised medicine.

Watch Pamela Gan’s talk at London Calling 2025

Sample type: cell lines, human blood

Kit: ligation sequencing kit, native barcoding kit

Authors: Pamela Gan Hui Peng, Yeo Han Lin, Muhammad Irfan Bin Hajis, Yusuf Maulana, Audrey Ng Qi Hui, Kevin Nathanael Ramanto, Marta Nisita Dewanggana, Astrid Irwanto, Levana Sani, Ling Goh Liuh, Mar Gonzalez-Porta

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
English flag